S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Stealth BioTherapeutics Stock Price, News & Analysis (NASDAQ:MITO)

$6.60
+0.79 (+13.60 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$6.08
Now: $6.60
$6.60
50-Day Range
$5.22
MA: $6.88
$9.06
52-Week Range
$4.97
Now: $6.60
$20.99
Volume34,094 shs
Average Volume104,251 shs
Market Capitalization$231.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in Newton, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MITO
CUSIPN/A
CIKN/A
Phone617-600-6888

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($13.84) per share

Profitability

Miscellaneous

Employees57
Market Cap$231.20 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive MITO News and Ratings via Email

Sign-up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter.


Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04. View Stealth BioTherapeutics' Earnings History.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Stealth BioTherapeutics.

What price target have analysts set for MITO?

6 brokers have issued twelve-month price objectives for Stealth BioTherapeutics' stock. Their forecasts range from $9.00 to $35.00. On average, they anticipate Stealth BioTherapeutics' stock price to reach $23.33 in the next year. This suggests a possible upside of 253.5% from the stock's current price. View Analyst Price Targets for Stealth BioTherapeutics.

What is the consensus analysts' recommendation for Stealth BioTherapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stealth BioTherapeutics.

Has Stealth BioTherapeutics been receiving favorable news coverage?

Press coverage about MITO stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Stealth BioTherapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Stealth BioTherapeutics.

Who are some of Stealth BioTherapeutics' key competitors?

What other stocks do shareholders of Stealth BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include Cronos Group (CRON), Paypal (PYPL), Tesla (TSLA), United Continental (UAL), Teck Resources (TECK), Twitter (TWTR), American Airlines Group (AAL), Applied Materials (AMAT), Activision Blizzard (ATVI) and Cerecor (CERC).

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the folowing people:
  • Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 54)
  • Mr. Daniel E. Geffken, Interim Chief Financial Officer (Age 62)
  • Mr. Mark J. Bamberger, Chief Scientific Officer (Age 66)
  • Mr. Henry Hess, Chief Legal Counsel
  • Dr. Ben R. Bronstein, Chief Medical Officer (Age 69)

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets served as the underwriters for the IPO and Nomura was co-manager.

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $6.60.

How big of a company is Stealth BioTherapeutics?

Stealth BioTherapeutics has a market capitalization of $231.20 million. The company earns $-96,710,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Stealth BioTherapeutics employs 57 workers across the globe.View Additional Information About Stealth BioTherapeutics.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is http://www.stealthbt.com/.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]


MarketBeat Community Rating for Stealth BioTherapeutics (NASDAQ MITO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about Stealth BioTherapeutics and other stocks. Vote "Outperform" if you believe MITO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MITO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel